174 related articles for article (PubMed ID: 16351678)
1. Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients?
Waters LJ; Nelson MR
Int J Clin Pract; 2005 Dec; 59(12):1452-8. PubMed ID: 16351678
[TBL] [Abstract][Full Text] [Related]
2. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
3. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
Joly V; Descamps D; Yeni P
AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
[TBL] [Abstract][Full Text] [Related]
4. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
[TBL] [Abstract][Full Text] [Related]
5. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
[TBL] [Abstract][Full Text] [Related]
6. Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy.
Clumeck N
Antivir Ther; 1998; 3 Suppl 4():39-43. PubMed ID: 10723508
[TBL] [Abstract][Full Text] [Related]
7. Stavudine-based multiple agent combinations: initial studies and ongoing comparative trials.
Murphy RL
Antivir Ther; 1998; 3 Suppl 4():69-73. PubMed ID: 10723516
[TBL] [Abstract][Full Text] [Related]
8. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
[TBL] [Abstract][Full Text] [Related]
9. The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome.
Nolan D; Mallal S
J HIV Ther; 2004 May; 9(2):34-40. PubMed ID: 15238874
[TBL] [Abstract][Full Text] [Related]
10. A rational approach to the selection and sequencing of nucleoside/nucleotide analogues: a new paradigm.
Lange J
Antivir Ther; 2001; 6 Suppl 3():45-54. PubMed ID: 11678472
[TBL] [Abstract][Full Text] [Related]
11. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.
Bartlett JA; Fath MJ; Demasi R; Hermes A; Quinn J; Mondou E; Rousseau F
AIDS; 2006 Oct; 20(16):2051-64. PubMed ID: 17053351
[TBL] [Abstract][Full Text] [Related]
12. Essential benefits of nucleoside analogue regimens in failing therapy.
Geretti AM
J HIV Ther; 2004 May; 9(2):28-33. PubMed ID: 15238873
[TBL] [Abstract][Full Text] [Related]
13. Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use.
Barreiro P; García-Benayas T; Soriano V; Gallant J
AIDS Rev; 2002; 4(4):233-41. PubMed ID: 12555697
[TBL] [Abstract][Full Text] [Related]
14. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
Ananworanich J; Hirschel B; Sirivichayakul S; Ubolyam S; Jupimai T; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Schutz M; Snowden W; Ruxrungtham K;
Antivir Ther; 2006; 11(5):631-5. PubMed ID: 16964832
[TBL] [Abstract][Full Text] [Related]
15. Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.
Naggie S; Hicks C
J Antimicrob Chemother; 2010 Jun; 65(6):1094-9. PubMed ID: 20418273
[TBL] [Abstract][Full Text] [Related]
16. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
Valantin MA; Lanoy E; Bentata M; Kalmykova O; Boutekadjirt A; Allavena C; Rozenbaum W; Peytavin G; Amellal B; Calvez V; Costagliola D; Katlama C;
HIV Med; 2008 Oct; 9(8):625-35. PubMed ID: 18624724
[TBL] [Abstract][Full Text] [Related]
17. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin L; Allavena C; Morlat P; Dellamonica P
AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
[TBL] [Abstract][Full Text] [Related]
18. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Jaspan HB; Berrisford AE; Boulle AM
Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
[TBL] [Abstract][Full Text] [Related]
19. The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens.
Arribas JR
J Antimicrob Chemother; 2004 Sep; 54(3):587-92. PubMed ID: 15282236
[TBL] [Abstract][Full Text] [Related]
20. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]